Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 11/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | PREP | P48147 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3170475 | 1.00 | DPP4 (0.47) | DPP4CHRM2CHRM4CHRM5PREP | |
| SCHEMBL13480299 | 0.79 | CHRM2 (0.42) | DPP4CHRM2CHRM4CHRM5SIGMAR1 | |
| SCHEMBL13680133 | 0.79 | CHRM2 (0.42) | DPP4CHRM2CHRM4CHRM5SIGMAR1 | |
| SCHEMBL3274071 | 0.75 | DPP4 (0.45) | DPP4CHRM2CHRM4CHRM5PREP | |
| SCHEMBL24685658 | 0.72 | CHRM2 (0.45) | CHRM2CHRM4CHRM5SIGMAR1 | |
| SCHEMBL12830800 | 0.70 | CHRM2 (0.59) | CHRM2CHRM4CHRM5SIGMAR1 | |
| SCHEMBL9677809 | 0.70 | MAPT (0.44) | SIGMAR1 | |
| SCHEMBL25079048 | 0.70 | CHRM2 (0.59) | CHRM2CHRM4CHRM5SIGMAR1 | |
| SCHEMBL10057896 | 0.70 | DPP4 (0.42) | DPP4 | |
| SCHEMBL4521492 | 0.69 | CHRM2 (0.53) | CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1997489-A1 | Adamantylglycine derivatives as inhibitors of dipeptidyl peptidase IV for the treatment of diabetes | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-03 | — | — | EP | disclosed |
| WO-2005012249-A2 | ADAMANTYGLYCINE- BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OF DIABETES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-10 | — | — | WO | disclosed |